EOI: Developing an “ultra fast-acting” Insulin

Agency: 
JDRF

The current EOI is targeted towards the identification of novel insulin formulations and improved strategies for delivery. As such, the EOI aims to gather information about innovative insulin molecules or delivery approaches that may mimic the postprandial action of endogenous human insulin better than existing formulations.

Deadline: 
April 6, 2009

Last updated March 19, 2009